QBI is hosting an event with expert, renowned speakers who will contribute to candid discussions between academia, industry and venture capitalists on “Optimizing the Transition from Science to Drugs.”  The event includes a line up of academic thought leaders, industry veterans, leading venture capitalists, and biotech media who will discuss how these key contributors can work more efficiently to turn scientific innovations into breakthrough therapies.

AGENDA

10:00 AM – Opening remarks

10:20 AM – Panel 1: Current State of Affairs of Academia/VC Relationships

Jennifer Doudna, PhD – Professor, UC Berkeley

Matt Jacobson, PhD – Professor, UC San Francisco

Herbert “Skip” Virgin, MD, PhD – Professor, Washington University 

Moderated by Carol Suh – Partner, ARCH Venture Partners 

11:00 AM – Break

11:30 AM – Panel 2: Altos Labs: A Different Approach

Hal Barron, MD – CEO, Altos Labs 

Catherine Lucey, MD – Executive Vice Chancellor & Provost, UC San Francisco

Moderated by George Scangos, PhD – Biotech Veteran 

12:10 PM – Panel 3: How Do We Optimize Academia/Industry Relationships?

Vineeta Agarwala, MD, PhD – General Partner, a16z

Nevan Krogan, PhD – Director, QBI 

George Scangos, PhD – Biotech Veteran 

Moderated by Ron Leuty – Senior Reporter, SF Business Times

12:50 PM – Lunch Reception